Recently, suramin has been shown to interfere with intracellular signalling proteins in the WNT pathway to inhibit the growth of breast cancer cells in a mouse xenograft model [48], and to target SH2 domains of STAT5a/b and STAT1 [49]. Here, STAT1 is linked to breast cancer.